The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 08, 2019
Filed:
May. 02, 2014
Applicant:
Selecta Biosciences, Inc., Watertown, MA (US);
Inventors:
Roberto A. Maldonado, Jamaica Plain, MA (US);
Takashi Kei Kishimoto, Lexington, MA (US);
Assignee:
Selecta Biosciences, Inc., Watertown, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/436 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 38/37 (2006.01); A61K 38/43 (2006.01); A61K 45/06 (2006.01); A61K 31/192 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); C07K 16/40 (2006.01); A61K 38/47 (2006.01); A61K 47/69 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/436 (2013.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 9/5115 (2013.01); A61K 9/5153 (2013.01); A61K 9/5192 (2013.01); A61K 31/192 (2013.01); A61K 38/19 (2013.01); A61K 38/21 (2013.01); A61K 38/37 (2013.01); A61K 38/43 (2013.01); A61K 38/47 (2013.01); A61K 39/3955 (2013.01); A61K 39/39533 (2013.01); A61K 45/06 (2013.01); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 47/6935 (2017.08); A61K 47/6937 (2017.08); C07K 16/18 (2013.01); C07K 16/241 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C12Y 305/01001 (2013.01);
Abstract
Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.